Evaluation of a stable gonadotropin-releasing hormone analog in mice for the treatment of endocrine disorders and prostate cancer

Journal of Pharmacology and Experimental Therapeutics

Volumn 336, Issue 3, 2011, Pages 613-623

  Katsila, Theodora ^a   Balafas, Evangelos ^a   Liapakis, George ^b   Limonta, Patrizia ^c   Marelli, Marina Montagnani ^c   Gkountelias, Konstantinos ^b   Tselios, Theodore ^d   Kostomitsopoulos, Nikolaos ^a   Matsoukas, John ^d   Tamvakopoulos, Constantin ^a  

^a BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANALOG 1; CETRORELIX; DRUG METABOLITE; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; LEUPRORELIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; CANCER CELL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BINDING; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG TOLERABILITY; ENDOCRINE DISEASE; EVALUATION; FEMALE; HISTOPATHOLOGY; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CAPSULE; LIQUID CHROMATOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REPEATED DRUG DOSE; TANDEM MASS SPECTROMETRY; TESTIS; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE RELEASE;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; DRUG EVALUATION, PRECLINICAL; ENDOCRINE SYSTEM DISEASES; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MICE; MICE, INBRED C57BL; PROSTATIC NEOPLASMS; RECEPTORS, LHRH; TREATMENT OUTCOME;

EID: 79951964145     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.174375     Document Type: Article

References (40)

1. Adjei A, Love S, Johnson E, Diaz G, Greer J, Haviv F, and Bush E (1993) Effect of formulation adjuvants on gastrointestinal absorption of leuprolide acetate. J Drug Target 1:251-258.
2. Anderes KL, Luthin DR, Castillo R, Kraynov EA, Castro M, Nared Hood K, Gregory ML, Pathak VP, Christie LC, Paderes G, et al. (2003) Biological characterization of a novel, orally active small molecule gonadotropin-releasing hormone (GnRH) antagonist using castrated and intact rats. J Pharmacol Exp Ther 305:688-695. (Pubitemid 36459188)
3. Berger H, Heinrich N, Albrecht E, Kertscher U, Oehlke J, Bienert M, Schäfer H, Baeger I, and Mehlis B (1991) Gonadotropin-releasing hormone (GnRH) analogs: relationship between their structure, proteolytic inactivation and pharmacokinetics in rats. Regul Pept 33:299-311.
4. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
5. Brudel M, Kertscher U, Berger H, and Mehlis B (1994) Liquid chromatographic-mass spectrometric studies on the enzymatic degradation of gonadotropin-releasing hormone. J Chromatogr A 661:55-60. (Pubitemid 24065336)
6. Carone FA and Peterson DR (1980) Hydrolysis and transport of small peptides by the proximal tubule. Am J Physiol 238:F151-F158. (Pubitemid 10118194)
7. 50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
8. Cleverly K and Wu TJ (2010) Is the metalloendopeptidase EC 3.4.24.15 (EP24.15), the enzyme that cleaves luteinizing hormone-releasing hormone (LHRH), an activating enzyme? Reproduction 139:319-330.
9. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, and Klocker H (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54:5474-5478.
10. Green B and Leak RE (1987) Steroid Hormones: A Practical Approach, IRL Press, Oxford, UK.
11. Halmos G, Schally AV, Pinski J, Vadillo-Buenfil M, and Groot K (1996) Downregulation of pituitary receptors for luteinizing hormone-releasing hormone (LHRH) in rats by LH-RH antagonist Cetrorelix. Proc Natl Acad Sci USA 93:2398-2402. (Pubitemid 26104795)
12. Haviv F, Fitzpatrick TD, Nichols CJ, Swenson RE, Bush EN, Diaz G, Nguyen A, Nellans HN, Hoffman DJ, Ghanbari H, et al. (1992) Stabilization of the N-terminal residues of the luteinizing hormone-releasing hormone agonists and the effect on pharmacokinetics. J Med Chem 35:3890-3894.
13. Huggins CB (1963) The hormone-dependent cancers. Bull NY Acad Med 39:752-757.
14. Johns WD, Garnick MB, and Kaplan WD (1990) Leuprolide therapy for prostate cancer. An association with scintigraphic "flare" on bone scan. Clin Nucl Med 15:485-487.
15. 9]GnRH: stimulation of gonadotropin gene expression. J Med Chem 49:105-110.
16. Kirby RS, Fitzpatrick JM, and Clarke N (2009) Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer. BJU Int 104:1580-1584.
17. Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez J, and Candas B (2005) Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 26:361-379. (Pubitemid 40686649)
18. Laimou DK, Katsara M, Matsoukas MT, Apostolopoulos V, Troganis AN, and Tselios TV (2010) Structural elucidation of Leuprolide and its analogues in solution: insight into their bioactive conformation. Amino Acids 39:1147-1160.
19. Limonta P, Dondi D, Moretti RM, Maggi R, and Motta M (1992) Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 75:207-212.
20. Limonta P, Moretti RM, Marelli MM, Dondi D, Parenti M, and Motta M (1999) The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 140:5250-5256.
21. Matsoukas J, Keramida M, Panagiotopoulos D, Mavromoustakos T, Maia HLS, Bigam G, Pati D, Habibi HR, and Moore GJ (1997) Structure elucidation and conformational analysis of gonadotropin releasing hormone and its novel synthetic analogue [Tyr(OMe)5,d-Lys6,Aze9NHEt]GnRH: the importance of aromatic clustering in the receptor binding activity. Eur J Med Chem 32:927-940. (Pubitemid 28037243)
22. Maudsley S, Davidson L, Pawson AJ, Chan R, López de Maturana R, and Millar RP (2004) Gonadotropin-releasing hormone (GnRH) antagonists promote proapoptotic signaling in peripheral reproductive tumor cells by activating a Galphai-coupling state of the type I GnRH receptor. Cancer Res 64:7533-7544. (Pubitemid 39372098)
23. Mezo G and Manea M (2010) Receptor-mediated tumor targeting based on peptide hormones. Expert Opin Drug Deliv 7:79-96.
24. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, and Maudsley SR (2004) Gonadotropin-releasing hormone receptors. Endocr Rev 25:235-275. (Pubitemid 38501395)
25. Montagnani Marelli M, Moretti RM, Januszkiewicz-Caulier J, Motta M, and Limonta P (2006) Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients? Curr Cancer Drug Targets 6:257-269.
26. Montagnani Marelli M, Moretti RM, Mai S, Procacci P, and Limonta P (2007) Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. Int J Oncol 30:261-271.
27. Montagnani Marelli M, Moretti RM, Mai S, Procacci P, and Limonta P (2008) Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo. Cancer Res 68:6331-6340.
28. Pawson AJ, Faccenda E, Maudsley S, Lu ZL, Naor Z, and Millar RP (2002) A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer. Clin Ther 24:1902-1914.
29. Pawson AJ, Faccenda E, Maudsley S, Lu ZL, Naor Z, and Millar RP (2008) Mammalian type I gonadotropin-releasing hormone receptors undergo slow, constitutive, agonist-independent internalization. Endocrinology 149:1415-1422. (Pubitemid 351397936)
30. Persson BE, Kold Olesen T, and Jensen JK (2009) Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology 90:235-244.
31. Schally AV, Redding TW, and Comaru-Schally AM (1984) Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treat Rep 68: 281-289. (Pubitemid 14192178)
32. Sealfon SC, Weinstein H, and Millar RP (1997) Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev 18: 180-205. (Pubitemid 27171519)
33. Sennello LT, Finley RA, Chu SY, Jagst C, Max D, Rollins DE, and Tolman KG (1986) Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. J Pharm Sci 75:158-160. (Pubitemid 16125665)
34. Sharpless NE and Depinho RA (2006) The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov 5: 741-754. (Pubitemid 44323701)
35. Shiota M, Tokuda N, Kanou T, and Yamasaki H (2007) Incidence rate of injection-site granulomas resulting from the administration of luteinizing hormone-releasing hormone analogues for the treatment of prostatic cancer. Yonsei Med J 48:421-424. (Pubitemid 47083087)
36. Sofianos ZD, Katsila T, Kostomitsopoulos N, Balafas V, Matsoukas J, Tselios T, and Tamvakopoulos C (2008) In vivo evaluation and in vitro metabolism of leuprolide in mice - mass spectrometry-based biomarker measurement for efficacy and toxicity. J Mass Spectrom 43:1381-1392.
37. Turk BG, Dereli T, Dereli D, and Akalin T (2007) Leuprolide acetate-induced leukocytoclastic vasculitis. Acta Obstet Gynecol Scand 86:892-893. (Pubitemid 47035817)
38. Ueno H and Matsuo S (1991) High-performance liquid chromatography followed by radioimmunoassay for the determination of a luteinizing hormone-releasing hormone analogue, leuprorelin, and its metabolite. J Chromatogr 566:57-66.
39. Wirth MP, Hakenberg OW, and Froehner M (2007) Optimal treatment of locally advanced prostate cancer. World J Urol 25:169-176.
40. Zheng Y, Qiu Y, Lu MF, Hoffman D, and Reiland TL (1999) Permeability and absorption of leuprolide from various intestinal regions in rabbits and rats. Int J Pharm 185:83-92. (Pubitemid 29333099)